Cite
HARVARD Citation
Cook, J. et al. (2021). Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first‐line therapy in multiple myeloma. American journal of hematology. 96 (3), pp. 330-337. [Online].